Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bamlanivimab (Primary) ; Bamlanivimab (Primary) ; Etesevimab (Primary) ; Etesevimab (Primary)
  • Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Registrational; Therapeutic Use
  • Acronyms BLAZE-1
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 17 Jun 2023 Results assessing the pharmacokinetic, efficacy, and safety in COVID-19 patients treated with bamlanivimab and etesevimab, published in the Infectious Diseases and Therapy.
    • 24 Aug 2022 Planned number of patients changed from 3290 to 3360.
    • 24 Aug 2022 Planned End Date changed from 17 Dec 2021 to 27 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top